Review





Similar Products

abatacept orencia  (Bristol Myers)
90
Bristol Myers abatacept orencia
Abatacept Orencia, supplied by Bristol Myers, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/abatacept orencia/product/Bristol Myers
Average 90 stars, based on 1 article reviews
abatacept orencia - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
abatacept  (Bristol Myers)
90
Bristol Myers abatacept
Pairwise meta-analysis of the risk of all malignancies excluding non-melanomatous skin cancers between <t>abatacept</t> and biologic/targeted synthetic disease modifying anti-rheumatic drug groups of eligible observational cohort studies; expressed as incidence rate ratios with 95% CIs and depicted graphically as a forest plot. Exposure is reported in person-years. The relative weighting of each study from a random-effects model is shown. A fixed continuity correction of 0.1 was applied to all studies with zero events. Heterogeneity between studies was assessed using I2 statistics. b/tsDMARD, biologic/targeted synthetic disease modifying anti-rheumatic drugs; CI, confidence interval
Abatacept, supplied by Bristol Myers, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/abatacept/product/Bristol Myers
Average 90 stars, based on 1 article reviews
abatacept - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
abatacept  (Achlys Inc)
90
Achlys Inc abatacept
Pairwise meta-analysis of the risk of all malignancies excluding non-melanomatous skin cancers between <t>abatacept</t> and biologic/targeted synthetic disease modifying anti-rheumatic drug groups of eligible observational cohort studies; expressed as incidence rate ratios with 95% CIs and depicted graphically as a forest plot. Exposure is reported in person-years. The relative weighting of each study from a random-effects model is shown. A fixed continuity correction of 0.1 was applied to all studies with zero events. Heterogeneity between studies was assessed using I2 statistics. b/tsDMARD, biologic/targeted synthetic disease modifying anti-rheumatic drugs; CI, confidence interval
Abatacept, supplied by Achlys Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/abatacept/product/Achlys Inc
Average 90 stars, based on 1 article reviews
abatacept - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
ctla 4 ig  (Bio X Cell)
94
Bio X Cell ctla 4 ig
Pairwise meta-analysis of the risk of all malignancies excluding non-melanomatous skin cancers between <t>abatacept</t> and biologic/targeted synthetic disease modifying anti-rheumatic drug groups of eligible observational cohort studies; expressed as incidence rate ratios with 95% CIs and depicted graphically as a forest plot. Exposure is reported in person-years. The relative weighting of each study from a random-effects model is shown. A fixed continuity correction of 0.1 was applied to all studies with zero events. Heterogeneity between studies was assessed using I2 statistics. b/tsDMARD, biologic/targeted synthetic disease modifying anti-rheumatic drugs; CI, confidence interval
Ctla 4 Ig, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ctla 4 ig/product/Bio X Cell
Average 94 stars, based on 1 article reviews
ctla 4 ig - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
adjuvant abatacept  (Atari Inc)
90
Atari Inc adjuvant abatacept
Pairwise meta-analysis of the risk of all malignancies excluding non-melanomatous skin cancers between <t>abatacept</t> and biologic/targeted synthetic disease modifying anti-rheumatic drug groups of eligible observational cohort studies; expressed as incidence rate ratios with 95% CIs and depicted graphically as a forest plot. Exposure is reported in person-years. The relative weighting of each study from a random-effects model is shown. A fixed continuity correction of 0.1 was applied to all studies with zero events. Heterogeneity between studies was assessed using I2 statistics. b/tsDMARD, biologic/targeted synthetic disease modifying anti-rheumatic drugs; CI, confidence interval
Adjuvant Abatacept, supplied by Atari Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/adjuvant abatacept/product/Atari Inc
Average 90 stars, based on 1 article reviews
adjuvant abatacept - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Pairwise meta-analysis of the risk of all malignancies excluding non-melanomatous skin cancers between abatacept and biologic/targeted synthetic disease modifying anti-rheumatic drug groups of eligible observational cohort studies; expressed as incidence rate ratios with 95% CIs and depicted graphically as a forest plot. Exposure is reported in person-years. The relative weighting of each study from a random-effects model is shown. A fixed continuity correction of 0.1 was applied to all studies with zero events. Heterogeneity between studies was assessed using I2 statistics. b/tsDMARD, biologic/targeted synthetic disease modifying anti-rheumatic drugs; CI, confidence interval

Journal: Rheumatology (Oxford, England)

Article Title: Abatacept and the risk of malignancy: a meta-analysis across disease indications

doi: 10.1093/rheumatology/keaf114

Figure Lengend Snippet: Pairwise meta-analysis of the risk of all malignancies excluding non-melanomatous skin cancers between abatacept and biologic/targeted synthetic disease modifying anti-rheumatic drug groups of eligible observational cohort studies; expressed as incidence rate ratios with 95% CIs and depicted graphically as a forest plot. Exposure is reported in person-years. The relative weighting of each study from a random-effects model is shown. A fixed continuity correction of 0.1 was applied to all studies with zero events. Heterogeneity between studies was assessed using I2 statistics. b/tsDMARD, biologic/targeted synthetic disease modifying anti-rheumatic drugs; CI, confidence interval

Article Snippet: Further to this, an evaluation of data from the Bristol Myers Squibb abatacept development programme suggested that abatacept significantly increased the risk of NMSC compared with conventional synthetic DMARDs (csDMARDs) [pooled rate ratios (RR) 1.84, 95% CI 1.00–3.37], but not b/tsDMARDs (RR 1.11, 95% CI 0.98–1.26) [ ].

Techniques: